Denosumab for treating aneurysmal bone cysts in children.
Fiche publication
Date publication
juillet 2019
Journal
Orthopaedics & traumatology, surgery & research : OTSR
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ENTZ-WERLE Natacha
Tous les auteurs :
Raux S, Bouhamama A, Gaspar N, Brugières L, Entz-Werlé N, Mallet C, Dijoud F, Gouin F, Marec-Bérard P
Lien Pubmed
Résumé
Aneurysmal bone cyst (ABC) is a benign tumour whose progression involves the RANK/RANKL signalling pathway. Surgery is the reference standard treatment but carries risks that vary with the site of the tumour. Denosumab is a human monoclonal IgG2 antibody that targets the RANK/RANKL pathway and may therefore hold promise for inhibiting ABC progression. The objective of this study was to evaluate denosumab use in paediatric patients (younger than 18 years) with ABC and to describe the clinical and radiological outcomes, as well as the side effect profile.
Mots clés
Aneurysmal bone cyst, Denosumab, RANKL antagonist
Référence
Orthop Traumatol Surg Res. 2019 Jul 26;: